# A Dose Escalating Study to Assess the Safety and Tolerability of GT-001

> **NCT03490786** · PHASE1 · COMPLETED · sponsor: **Gila Therapeutics, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Feeding and Eating Disorders

## Interventions

- **DRUG:** GT-001

## Key facts

- **NCT ID:** NCT03490786
- **Lead sponsor:** Gila Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-16
- **Primary completion:** 2017-08-09
- **Final completion:** 2017-10-02
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2018-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03490786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03490786, "A Dose Escalating Study to Assess the Safety and Tolerability of GT-001". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03490786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*